Treatment of HIV-associated Kaposi's sarcoma with paclitaxel.
We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% CI 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies, including a randomised trial, are warranted.
Saville
M W
MW
National Cancer Institute, Bethesda, MD 20892, USA.
Lietzau
J
J
Pluda
J M
JM
Feuerstein
I
I
Odom
J
J
Wilson
W H
WH
Humphrey
R W
RW
Feigal
E
E
Steinberg
S M
SM
Broder
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D002927:Cimetidine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004155:Diphenhydramine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D003907:Dexamethasone; D002927:Cimetidine; D004155:Diphenhydramine; D017239:Paclitaxel